The anti-tumor effects of two selective HDAC6 inhibitors, ricolinostat and citarinostat, have been investigated clinically as a combination-based regimen and demonstrated good response in relapsed multiple myeloma [75, 76]. Here, HDAC6 is linked to neoplasm.